Skip to main content
Top
Published in: International Journal of Clinical Oncology 3/2012

01-06-2012 | Case Report

Hepatitis B virus reactivation associated with temozolomide for malignant glioma: a case report and recommendation for prophylaxis

Authors: Yasunori Fujimoto, Naoya Hashimoto, Manabu Kinoshita, Yuko Miyazaki, Satoshi Tanaka, Takayuki Yakushijin, Tetsuo Takehara, Naoki Kagawa, Toshiki Yoshimine

Published in: International Journal of Clinical Oncology | Issue 3/2012

Login to get access

Abstract

Hepatitis B virus (HBV) reactivation during anticancer chemotherapy or immunosuppressive therapy in chronic carriers can lead to fatal liver failure. We report a rare case of severe HBV reactivation during postoperative radiotherapy with concomitant and adjuvant temozolomide (TMZ) for malignant glioma. A 49-year-old Japanese woman with a history of HBV carrier status with positive results for hepatitis B surface antigen presented with persistent headache due to a tumor in the left frontal lobe. The tumor was partially resected and anaplastic astrocytoma was diagnosed. Postoperative liver function was normal and radiotherapy plus concomitant and adjuvant TMZ was started. Impaired liver function became apparent just before administration of adjuvant TMZ, and acute liver failure developed. Antiviral therapy including entecavir, a nucleoside analog, led to a successful outcome and the patient survived. This case underlines the possibility of HBV reactivation due to TMZ and suggests the utility of HBV screening and antiviral prophylaxis before administration of TMZ to patients with malignant glioma.
Literature
1.
go back to reference Galbraith RM, Eddleston AL, William R et al (1975) Fulminating hepatic failure in leukemia and choriocarcinoma related to withdrawal of cytotoxic drug chemotherapy. Lancet 2:528–530PubMedCrossRef Galbraith RM, Eddleston AL, William R et al (1975) Fulminating hepatic failure in leukemia and choriocarcinoma related to withdrawal of cytotoxic drug chemotherapy. Lancet 2:528–530PubMedCrossRef
2.
go back to reference Lalazar G, Rund D, Shouval D (2007) Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 136:699–712PubMedCrossRef Lalazar G, Rund D, Shouval D (2007) Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 136:699–712PubMedCrossRef
3.
go back to reference Law JK, Ho JK, Hoskins PJ et al (2005) Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations. Leuk Lymphoma 46:1085–1089PubMedCrossRef Law JK, Ho JK, Hoskins PJ et al (2005) Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations. Leuk Lymphoma 46:1085–1089PubMedCrossRef
4.
go back to reference Yeo W, Chan PK, Zhong S et al (2000) Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 62:299–307PubMedCrossRef Yeo W, Chan PK, Zhong S et al (2000) Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 62:299–307PubMedCrossRef
5.
go back to reference Yeo W, Zee B, Zhong S et al (2004) Comprehensive analysis undergoing cytotoxic chemotherapy. Br J Cancer 90:1306–1311PubMedCrossRef Yeo W, Zee B, Zhong S et al (2004) Comprehensive analysis undergoing cytotoxic chemotherapy. Br J Cancer 90:1306–1311PubMedCrossRef
6.
go back to reference Stupp R, Dietrich PY, Ostermann Kraljevic S et al (2002) Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temosolomide. J Clin Oncol 20:1375–1382PubMedCrossRef Stupp R, Dietrich PY, Ostermann Kraljevic S et al (2002) Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temosolomide. J Clin Oncol 20:1375–1382PubMedCrossRef
7.
go back to reference Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Eng J Med 352:987–996CrossRef Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Eng J Med 352:987–996CrossRef
8.
go back to reference Chheda MG, Drappatz J, Greenberger NJ et al (2007) Hepatitis B reactivation during glioblastoma treatment with temozolomide: a cautionary note. Neurology 68:955–956PubMedCrossRef Chheda MG, Drappatz J, Greenberger NJ et al (2007) Hepatitis B reactivation during glioblastoma treatment with temozolomide: a cautionary note. Neurology 68:955–956PubMedCrossRef
9.
go back to reference Grewal J, Dellinger CA, Yung WKA (2007) Fatal reactivation of hepatitis B with temozolomide. N Eng J Med 356:1591–1592CrossRef Grewal J, Dellinger CA, Yung WKA (2007) Fatal reactivation of hepatitis B with temozolomide. N Eng J Med 356:1591–1592CrossRef
10.
go back to reference Leaw SJ, Yen CJ, Huang WT et al (2004) Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy. Ann Hematol 83:270–275PubMedCrossRef Leaw SJ, Yen CJ, Huang WT et al (2004) Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy. Ann Hematol 83:270–275PubMedCrossRef
11.
go back to reference Markovic S, Drozina G, Vovk M et al (1999) Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients. Hepatogastroenterology 46:2925–2930PubMed Markovic S, Drozina G, Vovk M et al (1999) Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients. Hepatogastroenterology 46:2925–2930PubMed
12.
go back to reference Kohrt HE, Ouyang DL, Keeffe EB (2006) Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Aliment Pharmacol Ther 24:1003–1016PubMedCrossRef Kohrt HE, Ouyang DL, Keeffe EB (2006) Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Aliment Pharmacol Ther 24:1003–1016PubMedCrossRef
13.
go back to reference Lok ASF, Liang RHS, Chiu EKW et al (1991) Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 100:182–188 Lok ASF, Liang RHS, Chiu EKW et al (1991) Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 100:182–188
14.
go back to reference Tur-Kaspa R, Burk RD, Shaul Y et al (1986) Hepatitis B virus DNA contains a glucocorticoid-responsive element. Proc Natl Acad Sci USA 83:1627–1631PubMedCrossRef Tur-Kaspa R, Burk RD, Shaul Y et al (1986) Hepatitis B virus DNA contains a glucocorticoid-responsive element. Proc Natl Acad Sci USA 83:1627–1631PubMedCrossRef
15.
go back to reference Pei SN, Chen CH, Lee CM et al (2010) Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HbsAg-negative patients. Ann Hematol 89:255–262PubMedCrossRef Pei SN, Chen CH, Lee CM et al (2010) Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HbsAg-negative patients. Ann Hematol 89:255–262PubMedCrossRef
16.
17.
go back to reference Lok ASF, NcMahon BJ (2009) Chronic hepatitis B: update 2009. Heapatology 50:661–662CrossRef Lok ASF, NcMahon BJ (2009) Chronic hepatitis B: update 2009. Heapatology 50:661–662CrossRef
18.
go back to reference Lubel JS, Testro AG, Angus PW (2007) Hepatitis B virus reactivation following immunosuppressive therapy: guidelines for prevention and management. Intern Med J 37:705–712PubMedCrossRef Lubel JS, Testro AG, Angus PW (2007) Hepatitis B virus reactivation following immunosuppressive therapy: guidelines for prevention and management. Intern Med J 37:705–712PubMedCrossRef
19.
go back to reference Tsubouchi H, Kumada H, Kiyosawa K et al (2009) Prevention of immunosuppressive therapy or chemotherapy-induced reactivation of hepatitis B virus infection–Joint report of the Intractable Liver Disease Study Group of Japan and the Japanese Study Group of the Standard Antiviral Therapy for Viral Hepatitis (in Japanese). Kanzo 50:38–42CrossRef Tsubouchi H, Kumada H, Kiyosawa K et al (2009) Prevention of immunosuppressive therapy or chemotherapy-induced reactivation of hepatitis B virus infection–Joint report of the Intractable Liver Disease Study Group of Japan and the Japanese Study Group of the Standard Antiviral Therapy for Viral Hepatitis (in Japanese). Kanzo 50:38–42CrossRef
20.
go back to reference Idilman R (2006) Duration of lamivudine prophylaxis in inactive hepatitis B virus carriers with haemato/oncological malignancies who receive chemotherapy. Gut 55:1208–1209PubMed Idilman R (2006) Duration of lamivudine prophylaxis in inactive hepatitis B virus carriers with haemato/oncological malignancies who receive chemotherapy. Gut 55:1208–1209PubMed
22.
go back to reference Tanaka J, Koyama T, Mizui M et al (2011) Total number of undiagnosed carriers of hepatitis C and B viruses in Japan estimated by age- and area-specific prevalence on the national scale. Intervirology. doi:10.1159/000324525 Tanaka J, Koyama T, Mizui M et al (2011) Total number of undiagnosed carriers of hepatitis C and B viruses in Japan estimated by age- and area-specific prevalence on the national scale. Intervirology. doi:10.​1159/​000324525
23.
go back to reference Fujisaki S, Yokomaku Y, Shiino T et al (2011) Outbreak of infections by hepatitis B virus genotype A and transmission of genetic drug resistance in patients coinfected with HIV-1 in Japan. J Clin Microbiol 49:1017–1024PubMedCrossRef Fujisaki S, Yokomaku Y, Shiino T et al (2011) Outbreak of infections by hepatitis B virus genotype A and transmission of genetic drug resistance in patients coinfected with HIV-1 in Japan. J Clin Microbiol 49:1017–1024PubMedCrossRef
Metadata
Title
Hepatitis B virus reactivation associated with temozolomide for malignant glioma: a case report and recommendation for prophylaxis
Authors
Yasunori Fujimoto
Naoya Hashimoto
Manabu Kinoshita
Yuko Miyazaki
Satoshi Tanaka
Takayuki Yakushijin
Tetsuo Takehara
Naoki Kagawa
Toshiki Yoshimine
Publication date
01-06-2012
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 3/2012
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-011-0294-3

Other articles of this Issue 3/2012

International Journal of Clinical Oncology 3/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine